In 2008, I was exposed to absurd censorship and editorial misconduct when I tried to publish a Cochrane review of an obscenely expensive drug, alpha-1 antitrypsin for patients with lung disease caused by inherited alpha-1 antitrypsin deficiency. I have also been exposed to censorship in relation to our assessment of the quality of 53 new Cochrane reviews, mammography screening, house dust mites, antidepressants, and most recently, in February 2025, in relation to our update of the mammography screening review. Cochrane has fallen so deep now that it seems to be beyond repair. Read my article.